New Therapeutics for Chronic Heart Failure
- 1 February 2002
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 59-74
- https://doi.org/10.1146/annurev.med.53.082901.104004
Abstract
▪ Abstract Traditionally, clinicians have viewed heart failure either as a problem of excessive salt and water retention caused by abnormalities of renal blood flow, or as a hemodynamic problem associated with a reduced cardiac output and excessive peripheral vasoconstriction. Recently, clinicians have begun to adopt a neurohormonal model in which heart failure progresses because of the toxic effects of endogenous biological systems that become activated in heart failure. We review the rationale for existing heart failure therapies and discuss the reasoning behind the development of some emerging therapies.Keywords
This publication has 34 references indexed in Scilit:
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failurePublished by Elsevier ,2010
- IntroductionThe American Journal of Cardiology, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Improving Outcomes in Congestive Heart Failure: Val-HeFTCardiology, 1999
- Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathyThe Lancet, 1998
- Inhibition of myocardial endothelin pathway improves long-term survival in heart failureNature, 1996
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- The Adrenergic Nervous System in Heart FailureNew England Journal of Medicine, 1984
- Prostaglandins in Severe Congestive Heart FailureNew England Journal of Medicine, 1984